Your session is about to expire
← Back to Search
DYNE-251 for Duchenne Muscular Dystrophy (DELIVER Trial)
DELIVER Trial Summary
This trial is testing a new drug to treat Duchenne Muscular Dystrophy. The drug will be given intravenously to participants and the safety, tolerability, and effectiveness of the drug will be monitored over the course of 24 weeks.
DELIVER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DELIVER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received gene therapy before.I haven't taken any experimental drugs that don't target gene skipping in the last 4 months.I do not have uncontrolled symptoms of heart failure.I am between 4 and 16 years old.A muscle in my arm can be safely biopsied.My lung function is less than 40% of what is expected for my age.I can lift my arms above my head without help.I have received eteplirsen or a similar therapy in the last 12 weeks.I am a male with a specific genetic change in my dystrophin gene that can be treated by targeting exon 51.I need help from a machine to breathe during the day.I have been unable to walk for less than 2 years.I haven't had major surgery in the last 12 weeks and don't expect any during the study.I have been on a stable dose of glucocorticoids for at least 12 weeks.My heart failure treatment hasn't changed in the last 3 months.
- Group 1: Placebo-Controlled MAD Period - DYNE-251
- Group 2: Placebo-Controlled MAD Period - Placebo
- Group 3: Open-Label and Long-Term Extension Period - DYNE-251
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the eligibility criteria for this trial encompass individuals aged 45 and older?
"This trial is seeking participants that are in the 4 to 16 year old demographic."
Are there any current opportunities to partake in this experiment?
"That is correct. According to the latest information uploaded on clinicaltrials.gov, this trial - which was first shared on August 12th 2022- is actively searching for 46 patients across 3 medical centres."
Who can qualify for participation in this trial?
"This clinical trial is recruiting 46 boys aged 4 to 16 with Duchenne muscular dystrophy. In addition, they must have an upper extremity Brooke Upper Extremity Scale score of 1 or 2, be ambulatory or non-ambulatory for less than two years prior to enrolment, and receiving a stable dosage of glucocorticoids for at least 12 weeks before treatment begins as well as having a left ventricular ejection fraction measured by echocardiogram or cardiac magnetic resonance imaging over 50%."
What is the current recruitment number for participants of this trial?
"Affirmative. According to clinicaltrials.gov, this medical investigation began on August 12th 2022 and is presently enrolling 46 patients between 3 sites. The listing was most recently updated on October 21st 2022."
Share this study with friends
Copy Link
Messenger